Tetraphase Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

WATERTOWN, Mass., March 27, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 10:00 a.m. Eastern Time at the Westin NY Grand Central Hotel in New York City.

A live audio webcast of the Needham presentation will be available on the company’s website at http://ir.tphase.com/events.cfm.  An archived presentation will be available for 30 days.

About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform.  Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.

Investor Contacts:
Tetraphase Pharmaceuticals 
Teri Dahlman 
617-600-7040
[email protected]

Argot Partners
Maeve Conneighton
206-899-4940
[email protected]

Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
[email protected]

Source: Tetraphase Pharmaceuticals

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BRICS countries rally to counter shocks of power politics, unilateralism: China Daily editorial
• Hyundai Motor Group Accelerates Autonomous Driving Innovation with AI-Powered Data Flywheel
• Apeing’s $0.0004 Presale Nears Its Next Stage: 410M+ Sold as Traders Eye the Next Big Crypto Beyond ETH and AVAX